Treatment Patterns, Drug Survival, and Effectiveness of Tildrakizumab Among Patients with Prior Interleukin-17 Experience in the PPD CorEvitas Psoriasis Registry
{{output}}
Introduction: Tildrakizumab is an interleukin (IL)-23 p19 inhibitor approved for the treatment of adults with moderate-to-severe plaque psoriasis. This study assessed tildrakizumab effectiveness and drug survival in real-world pa... ...
